RECORD // Company

Attovia Therapeutics, Inc.

Built 2026-11-21T05:59:42Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Attovia Therapeutics Inc · Ctgov · same registered legal name as 'Attovia Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ATTOVIA THERAPEUTICS INC · Epa echo · same registered legal name as 'Attovia Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ATTOVIA THERAPEUTICS INC · Epa echo · same registered legal name as 'Attovia Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001193125-26-453622

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-09-3010-Q2026-11-090001193125-26-4536222026-11-21 05:59 UTCReport an error
Net income (loss)$-22,271,0003 months ended 2026-09-3010-Q2026-11-090001193125-26-4536222026-11-21 05:59 UTCReport an error
Cash and cash equivalents$115,366,000at 2026-09-3010-Q2026-11-090001193125-26-4536222026-11-21 05:59 UTCReport an error
Contract liabilities, current$0at 2026-09-3010-Q2026-11-090001193125-26-4536222026-11-21 05:59 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0002058707
Ticker
ATTO
EIN
921510574
CUSIP
04987L102
Record ID
sx:sec:0002058707

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

9 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 05:59 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profile2026-11-21 05:59 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 05:59 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 05:59 UTCReport an error
Business address1091 INDUSTRIAL ROAD, SAN CARLOS, CA, 940702026-11-16SEC EDGAR company profile2026-11-21 05:59 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 05:59 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, Attovia Therapeutics, Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by…2026-11-09SEC EDGAR 8-K 0001193125-26-453592 (text as filed, excerpt)2026-11-21 05:59 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-09)The Company recently announced positive topline 12-week results from its Phase 1b study of ATTO-1310, a next-generation anti-IL-31 ATTOBODY-based precision itch therapy, in patients with chronic pruritus (“CP”) and high-itch atopic dermatitis (“AD”). Favorable Tolerability ATTO-1310 was generally well tolerated in both healthy volunteers (“HV”) and patients. In the HV portion of the study, there was one treatment-emergent adverse event (“TEAE”) that led to treatment discontinuation due to Grade 1 fever. There were no TEAEs that led to study discontinuations in CP and AD patients. There was one serious TEAE (worsening of a pre-existing hiatal hernia), which was deemed unrelated to study…2026-11-09SEC EDGAR 8-K 0001193125-26-453592 (text as filed, excerpt)2026-11-21 05:59 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-09-02)On September 2, 2026, Attovia Therapeutics, Inc. (the “Company”) issued a press release reporting its financial results for the second quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by…2026-09-02SEC EDGAR 8-K 0001193125-26-380215 (text as filed, excerpt)2026-11-21 05:59 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.